BMO raises Eli Lilly stock price target on metabolic strength
BMO Capital raised its price target for Eli Lilly (NYSE:LLY) to $1,650, citing strong metabolic disease franchise performance and recent guidance increases. The stock, trading at $1,373.70, has surged 64% over the past year. Eli Lilly's revenue grew 46% to $86.5 billion, with an 84% gross profit margin. The company's Q3 2026 earnings of $7.48 per share beat expectations, with revenue of $24.4 billion. Several analysts raised their price targets following the strong results.
How this was made
The 30-second read
Why it matters
Analyst upgrade may drive buying interest and support share price.
Market read
Analyst upgrade could attract new investors and lift LLY stock.
What to watch
Potential regulatory hurdles and emerging competition in obesity market.
Background
Article summarizes BMO's price target raise for Eli Lilly and recaps recent earnings performance.
Ticker impact
BMO Capital raised its price target on Eli Lilly to $1,650, citing metabolic franchise strength and guidance uplift.
likely upside as investors price in stronger metabolic franchise outlook
Target increase reflects confidence in metabolic franchise and recent guidance raise, indicating potential share price appreciation.
Market effects
Strengthens outlook for pharma metabolic segment and obesity therapeutics.
May boost US biotech and pharma sentiment.
Could influence global pharmaceutical valuations and competitor positioning.
Counterpoint
Target may be overly optimistic given high valuation and competitive pressures.
Key entities
- companyEli Lilly
Pharmaceutical company with metabolic franchise focus.
- analyst_firmBMO Capital
Investment bank that raised the price target.
